Trifarotene

Chemical compound From Wikipedia, the free encyclopedia

Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris.[6][8] It is a retinoid;[6][9] specifically, a fourth-generation selective retinoic acid receptor (RAR)-γ agonist.[10]

Trade namesAklief, Selgamis
Other namesCD5789
AHFS/Drugs.comMonograph
MedlinePlusa620004
Quick facts Clinical data, Trade names ...
Trifarotene
Clinical data
Trade namesAklief, Selgamis
Other namesCD5789
AHFS/Drugs.comMonograph
MedlinePlusa620004
License data
Pregnancy
category
Routes of
administration		Topical
Drug classSkin and mucous membrane agents
ATC code
Legal status
Legal status
Identifiers
  • 4-[3-(3-tert-Butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.278.901 Edit this at Wikidata
Chemical and physical data
FormulaC29H33NO4
Molar mass459.586 g·mol−1
3D model (JSmol)
  • CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
  • InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
  • Key:MFBCDACCJCDGBA-UHFFFAOYSA-N
Close

Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).[11][12] It was approved for medical use in the United States in October 2019.[8][13][14] In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.[7]

Medical uses

In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.[6] In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older.[1][2][3]

Side effects

Most adverse effects of topical trifarotene for the treatment of acne are at the location site and transient, such as application site irritation, allergic dermatitis, skin irritation and sunburn.[15] Even though systemic absorption is very low,[16] use of trifarotene is still contraindicated during pregnancy[17] because of the known risk of teratogenicity of the overall class of drugs trifarotene belongs to, retinoids.

Society and culture

Trifarotene was approved for medical use in the United States in October 2019,[14] in Canada in November 2019,[3] and in Australia in January 2021.[1][2]

References

Related Articles

Wikiwand AI